|
|
|
|
|
Last Trade
|
Last Trade:
$10.29
|
Change:
-0.19 (-1.81%)
|
Trade Time:
09:30 AM EST
|
Market Cap:
$350.34M
|
|
|
|
|
|
|
Description of Business
|
|
We are a pharmaceutical company committed to developing and commercializing
innovative therapeutics to help improve the lives of patients with serious eye
disorders.
Our pipeline leverages our proprietary Durasert® technology for sustained
intraocular drug delivery including EYP-1901, a potential six-month anti-VEGF
treatment initially targeting wet age-related macular degeneration ("wet AMD"),
the leading cause of vision loss among people 50 years of age and older in the
United States. We also have two commercial products: YUTIQ®, a once every
three-year treatment for chronic non-infectious uveitis affecting the posterior
segment of the eye, and DEXYCU®, a single dose treatment for postoperative
inflammation following ocular surgery. We are also advancing YUTIQ 50, a
potential six-month treatment for non-infectious uveitis affecting the posterior
segment of the eye, one of the leading causes of blindness under a supplemental
New Drug Application ("sNDA") strategy.
|
|
|
|